Patent ID: 8808701

Claim:
A method for inhibiting the interaction of human C5aR with C5a, the method comprising exposing the human C5aR to a substantially purified and/or recombinant humanized antibody comprising i) an immunoglobulin light chain comprising a variable region comprising an amino acid sequence which is at least 95% identical to one or more of SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33 and SEQ ID NO:48, wherein the variable region comprises an amino acid sequence wherein the amino acid sequence of CDR-L1 is RSSQSLVHSNGNTYLH (SEQ ID NO:60), the amino acid sequence of CDR-L2 is KVSNRFS (SEQ ID NO:61) and the amino acid sequence of CDR-L3 is SQSTLVPLT (SEQ ID NO:62), and/or ii) an immunoglobulin heavy chain comprising a variable region comprising an amino acid sequence which is at least 95% identical to one or more of SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36 and SEQ ID NO:39, wherein the variable region comprises an amino acid sequence wherein the amino acid sequence of CDR-H1 is GYAFSNSWMN (SEQ ID NO:63), the amino acid sequence of CDR-H2 is RIYPGDGDTKYNGKFKG (SEQ ID NO:64) and the amino acid sequence of CDR-H3 is ARFLLISTVTAVDY(SEQ ID NO:65), wherein the antibody binds human C5aR.